The Efficacy of Dutasteride and Green Tea Combination Towards Angiogenesis and Bleeding on BPH after TURP : Study their effect on VEGF, MVD and Hb

Eriawan Agung Nugroho, Rifki Muslim, Ignatius Riwanto, Soetojo Wirjo Pranoto




Objectives: to find the efficacy dutasteride and green tea in reducing hemorrhage on TURP patients  and to evaluate the anti- angiogenesis effect.

Methods: Double Blind Randomized Controlled Trial Post Test Only, with 80 samples, randomized into 4 groups: 1 control group and 3 treatment groups (P1 with 0.5 mg of dutasteride, P2 with a capsul of green tea, and P3 with combination of 0.5 mg dutasteride and a capsul green tea at least 14 days before TURP. We compared the ΔHb define the VEGF expression and MVD count to evaluate the angiogenesis changes between 4 groups. The difference is considered statistically significant with p<.05.

Results: ΔHb (-0.40 + 0.246) pg/ml for control group, (-0.20 + 0.067) pg/ml for P1 group, (-0.18 + 0.081) pg/ml for P2 group, and (-0.14 + 0.092) pg/ml for P3 group. VEGF expression were (20.20 + 17.386), (12.90 + 15.509), (11.60 + 9.121), and (3.60 + 1.667) for control, P1, P2, and P3 group respectively. MVD count were (41.20  + 10.273), (32.75 + 9.318), (26.15 + 7.278), and (18.35 + 7.876) for control, P1, P2, and P3 group respectively. The result from between-subject effect tests showed statistically significant differences in ΔHb (p<0.001), VEGF expression (p<0.001), and MVD count (p<0.001). Dutasteride and green tea significantly reduce the hemorrhage during TURP by decreasing the MVD.

Conclusion: Administration of  0.5 mg dutasteride and 725 mg of green tea, 14 days prior to TURP significantly reduce the hemorrhage during TURP (Δ Hb) by decreasing the MVD


VEGF, MVD, Hb, Dutasteride, Green Tea

Full Text:



Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I-Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer. Cancer Res. 2004;64:8715–22

Ahmad N, Feyes D K, Nieminen AL, Agarwal R. Green Tea Constituent Epigallocatechin-3-gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma cells. J. Natl Cancer Ins. 1997. 89.

Carmeliet, P. And R. K. Jain. Angiogenesis in Cancer and Other Diseases. Nature 407 (6801) 2000: 249-57.

Chapple CR, Pharmacological Therapy Of Benign Prostatic/Lower Urinary Tract Symptoms : An Overview For The Practicing Clinician. BJU Int 2004 Vol94 : 738-44

Cilotti A, Danza G, Serio M. Clinical Application Of 5α Reductase Inhibitors. J. EndrocrinalInvest ; 24, 2001:199-203

Foley CL, Bott SR, Kirby RS. An Update On The 5 Alpha Reductase Inhibitor. Timely Top Med Urol 2003 Vol 4, Jun 2003

Fassina G, Venè R, Morini M, Mechanisms Of Inhibition Of Tumor Angiogenesis And Vascular Tumor Growth By Epigallocatechin-3-Gallate. Clinical Cancer Research 2004 Jul 15;10(14):4865-73.

J. Curtis Nickel. Comparison of Clinical Trials with Finasteride and Dutasteride. Rev Urol. 2004; 6(Suppl 9): 31-9

Jarvis TR, Chughtai B, Kaplan SA. Bladder Outlet Obstruction and BPH. Current Bladder Dysfunction Reports. 2014:7-1

Haggstrom S, Lissbrant IF, Bergh A, Damber J. Testosterone Induces Vascular Endothelial Growth Factor Synthesis In The Ventral Prostate In Castrated Rats, J Urol, 161, 1999: 1620-25

Landon Trost, Theodore R. Saitz BS and Wayne J.G. Hellstrom. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review Article first published online: 30 Apr 2013

Purnomo BB. Dasar-DasarUrologi. 3rd Ed. Jakarta: CV SagungSeto; 2011

Roehrborn CG, McConnel JD. Etiology, Pathophysiology, And Natural History Of Benign Prostatic Hyperplasia. In : Walsh PC, Retik AB, Vaughan ED Jr, Wein A Eds. Campbell’s Urology 8th Ed. WB Saunders. Philadelphia. 2002 : 1297-330.

Walsh PC, Retik AB. Transurethral Surgery. In : Campbell’s Urology 7th Ed. WB Saunders. Philadelphia, 1998 : 1511-28.

Published by Department of Chemical Engineering University of Diponegoro Semarang
Google Scholar

IJSE  by is licensed under Creative Commons Attribution 3.0 License.